Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 18Unknown 6Terminated 6Recruiting 5Not yet recruiting 3Withdrawn 2Active not recruiting 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 1328Neoplasms 998Carcinoma, Non-Small-Cell Lung 865Prostatic Neoplasms 730Colorectal Neoplasms 671Lung Neoplasms 553Leukemia, Myeloid, Acute 475Neoplasm Metastasis 427Pancreatic Neoplasms 426Carcinoma, Hepatocellular 407Ovarian Neoplasms 393Multiple Myeloma 393Stomach Neoplasms 383Recurrence 369Squamous Cell Carcinoma of Head and Neck 327Melanoma 295Uterine Cervical Neoplasms 288Brain Neoplasms 288Triple Negative Breast Neoplasms 273Glioblastoma 263Head and Neck Neoplasms 260Precursor Cell Lymphoblastic Leukemia-Lymphoma 256Endometrial Neoplasms 238Lymphoma 230Esophageal Neoplasms 226Rectal Neoplasms 224Sarcoma 213Carcinoma, Renal Cell 205Colonic Neoplasms 196Lymphoma, Large B-Cell, Diffuse 194

Interventions

Injections 2Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Interventional × Advanced Malignancies × Clear all
NCT06038058 2025-12-30

A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

BioRay Pharmaceutical Co., Ltd.

Phase 1 Recruiting
164 enrolled

Advanced Malignancies

NCT06937957 2025-11-21

A Study of BR111 in Patients With Advanced Malignancies

BioRay Pharmaceutical Co., Ltd.

Phase 1 Recruiting
166 enrolled

Advanced Malignancies

NCT06717880 2025-02-12

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1 Recruiting
260 enrolled

Advanced Malignancies

NCT04651348 2024-11-20

A Clinical Study of MIL95 in Advanced Malignancies.

Beijing Mabworks Biotech Co., Ltd.

Phase 1 Recruiting
58 enrolled

Advanced Malignancies

NCT06468098 2024-07-18

A Study of IBI363 in Subjects With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
556 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡